Abstract
Patients with chronic kidney disease (CKD) are at risk of both bleeding and thrombotic complications due to complex abnormalities in cellular, plasmatic and endothelial components of coagulation. Standard coagulation assays are unable to predict bleeding or thrombotic risk in patients with CKD. Comprehensive global assessment of haemostasis with thromboelastometry (TEM) is used in routine care in other clinical areas but their role in assessing the multifactorial defects in patients with CKD has not been explored.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
